[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tanta University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":590},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,202,0,25,[9,39,65,87,117,136,159,180,206,231,252,271,293,316,341,362,386,407,427,446,470,501,524,549,569],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100645410","detection-of-early-scapular-dyskinesis-100645410",false,"NCT07681999","Detection of Early Scapular Dyskinesis","Detection of Early Inflammatory Versus Early Mechanical Scapular Dyskinesis","Inclusion Criteria:\n\n* treatment-naïve patients with ankylosing spondylitis (AS), who fulfilled the Assessment of Spondylarthritis Society (ASAS) criteria for axial spondyloarthritis (ax-SpA)\n* Inclusion criterion for the second group (non-AS individuals) was patients complaining of discomfort upon activity.\n\nExclusion Criteria:\n\n* The exclusion criteria of the first group included:\n\n  1. patients with a history of local trauma\n  2. and\u002For surgical intervention,\n  3. neuromascular deficits,\n  4. chronic chest disease and\n  5. other inflammatory autoimmune\u002Frheumatologic conditions.\n* Exclusion criteria for the second group were:\n\n  1. a history of AS or\n  2. other systemic autoimmune\u002F rheumatologic disease.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This study is a prospective blind contrast between periscapular muscle thickness measured with MSUS in patients with early AS in comparison to patients with mechanical dyskinesis and to correlate it with EMG findings.",[25],"Scapular Dyskinesis","RECRUITING","2026-07-01",{"date":29,"type":30},"2026-07-02","ACTUAL",{"date":32,"type":30},"2026-06-19",{"date":34,"type":21},"2026-07",{"name":36,"class":37},"Tanta University","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":38},"100644971","microsurgical-single-versus-double-dartos-flap-in-distal-hypospadias-repair-100644971","NCT07676916","Microsurgical Single Versus Double Dartos Flap in Distal Hypospadias Repair","Microsurgical Single Versus Double Dartos Flap in Distal Hypospadias Repair: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Male patients diagnosed with Distal Hypospadias.\n* Age: From 6 months to 18 years.\n* Primary cases.\n* Uretheral Plate\\>8mm.\n* Glanular width≥14mm.\n\nExclusion Criteria:\n\n* Coronal and glanular hypospadias.\n* Severe chordee.\n* Associated disorders of sexual development.\n* Un-controlled bleeding disorders.","6 Months",{"count":20,"type":21},"INTERVENTIONAL",[50],"NA","This study aims to compare the surgical and functional outcomes of microsurgical single dartos flap versus double dartos flap in distal hypospadias repair.",[53,54,55,56],"Microsurgical","Single Dartos Flap","Double Dartos Flap","Distal Hypospadias Repair","2026-06-24",{"date":59,"type":30},"2026-06-30",{"date":61,"type":30},"2026-05-16",{"date":63,"type":21},"2027-04-01",{"name":36,"class":37},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":48,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":38},"100643880","intraarticular-injection-of-botox-and-hyaluronic-acid-in-knee-osteoarthritis-100643880","NCT07666347","Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Both genders.\n* Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis.\n* Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.\n\nExclusion Criteria:\n\n* History of intra-articular injection within the last 6 months,\n* History of surgery on the knee joint or major trauma to the lower limb causing fracture.\n* Body mass index (BMI) more than 40 kg\u002Fm2.\n* Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout.\n* Diabetic patient.\n* Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection.\n* Hypersensitivity to Botulinum toxin or hyaluronic acid.","50 Years",{"count":73,"type":21},50,[50],"This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.",[77,78,79,80],"Intraarticular Injection","Botox","Hyaluronic Acid","Knee Osteoarthritis",{"date":82,"type":30},"2026-06-25",{"date":57,"type":30},{"date":85,"type":21},"2026-12-01",{"name":36,"class":37},{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":48,"phases":99,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":38},"100644965","a-novel-suspensory-ligament-penodermal-fixation-technique-versus-dorsal-tunica-albuginea-fixation-for-pediatric-buried-penis-100644965","NCT07675915","A Novel Suspensory Ligament Penodermal Fixation Technique Versus Dorsal Tunica Albuginea Fixation for Pediatric Buried Penis:","A Novel Suspensory Ligament Penodermal Fixation Technique Versus Dorsal Tunica Albuginea Fixation for Pediatric Buried Penis: A Prospective Comparative Cohort Study","Inclusion Criteria:\n\n* Children under the age of 18 years diagnosed\n* Children with buried penis with parents seeking surgical treatment of this condition.\n\nExclusion Criteria:\n\n* History of previous penile surgery.\n* Patients with micro-penis.\n* Patients with other congenital anomalies such as hypospadias, epispadias and cryptorchidism.\n* Uncontrolled bleeding diathesis or patient who isn't fit for general anesthesia.\n* Buried penis due to excessive obesity.","MALE","2 Months","16 Years",{"count":98,"type":21},40,[50],"The aim of the work to compare the outcomes of suspensory ligament fixation to the sub-dermis and dorsal tunica albuginea fixation in terms of success rate, need for auxiliary procedures, and complication rates in the buried penis.",[102,103,104],"Penis\u002FSurgery","Fixation","Ligament",[106,107,108,109],"Suspensory Ligament","Penodermal","Dorsal Tunica Albuginea Fixation","Pediatric Buried Penis","NOT_YET_RECRUITING","2026-06-23",{"date":59,"type":30},{"date":59,"type":21},{"date":115,"type":21},"2027-07-30",{"name":36,"class":37},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":48,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":38},"100644127","cryoneurolysis-versus-radiofrequency-in-knee-osteoarthritis-100644127","NCT07664371","Cryoneurolysis Versus Radiofrequency in Knee Osteoarthritis","Cryoneurolysis Versus Radiofrequency in Knee Osteoarthritis: A Randomised Controlled Trial","Inclusion Criteria:\n\n1. adults between the ages of 30 and 70 years with a clinical diagnosis of refractory knee OA who suffered from knee pain.\n2. Patients who cannot afford intra-articular injections.\n3. patients who had failed 2 different oral pain medications, and 6 weeks of physical therapy.\n\nExclusion Criteria:\n\n1. Patients with OA show improvement in pain after physiotherapy.\n2. patients evaluated by an orthopedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.\n3. pregnant patients.\n4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.\n5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.\n6. people who had received an intra-articular knee injection within the last 6 months.\n7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.",{"count":125,"type":21},60,[50],"The project will evaluate the effectiveness of Cryoneurolysis versus radiofrequency procedures in adult patients who are resistant to traditional treatment for knee pain. They are a drug-free pain management procedure.",[80],{"date":130,"type":30},"2026-06-26",{"date":132,"type":30},"2026-06-10",{"date":134,"type":21},"2026-11",{"name":36,"class":37},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":48,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":38},"100640892","supra-iliac-anterior-quadratus-lumborum-block-and-pericapsular-nerve-group-peng-block-for-analgesia-after-total-hip-arthroplasty-100640892","NCT07606794","Supra-Iliac Anterior Quadratus Lumborum Block and Pericapsular Nerve Group (PENG) Block for Analgesia After Total Hip Arthroplasty","A Randomized Clinical Non-Inferiority Trial Comparing Supra-Iliac Anterior Quadratus Lumborum Block and Pericapsular Nerve Group (PENG) Block for Analgesia After Total Hip Arthroplasty","Inclusion Criteria:\n\n* Age from 18 to 75 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) classification I-III.\n* Scheduled for primary elective unilateral total hip arthroplasty (THA) under spinal anesthesia.\n\nExclusion Criteria:\n\n* Known allergies to the drugs used.\n* Infection at the injection site.\n* Bleeding disorders.\n* Recognized neuromuscular disorders.\n* Opioid addiction or dependence.\n* Contraindications to regional anesthesia or peripheral nerve blockade.\n* Body mass index (BMI) \\> 40 kg\u002Fm².\n* Associated decompensated cardiac, hepatic, respiratory, or renal diseases.","75 Years",{"count":73,"type":21},[50],"This study aims to compare the analgesic efficacy of supra-iliac anterior quadratus lumborum block (SA-QLB) and pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA).",[148,149,150,151],"Supra-Iliac Anterior Quadratus Lumborum Block","Pericapsular Nerve Group Block","Analgesia","Total Hip Arthroplasty","2026-06-22",{"date":111,"type":30},{"date":155,"type":30},"2026-05-23",{"date":157,"type":21},"2026-10-30",{"name":36,"class":37},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":48,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":38},"100634234","analgesic-efficacy-of-quadro-iliac-plane-block-versus-erector-spinae-plane-in-total-hip-arthroplasty-100634234","NCT07537036","Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty","Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty: A Randomized Non-Inferiority Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-III.\n* Undergoing total hip arthroplasty (THA) under spinal anesthesia.\n\nExclusion Criteria:\n\n* History of allergies to local anesthetics.\n* Opioid dependency.\n* Body mass index (BMI) \\> 35 kg\u002Fm2.\n* Cognitive impairment.\n* Bleeding or coagulation disorders.\n* Psychiatric and neurological disorder.\n* Local infection at the site of injection.\n* Severe heart, lung, liver, and renal dysfunction.\n* Emergency surgery.",{"count":167,"type":21},76,[50],"This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.",[171,172,173,151],"Analgesic Efficacy","Quadro-Iliac Plane Block","Erector Spinae Plane Block",{"date":111,"type":30},{"date":176,"type":30},"2026-04-18",{"date":178,"type":21},"2026-11-30",{"name":36,"class":37},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":187,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":48,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":38},"100632269","ondansetron-lozenge-versus-intravenous-for-prevention-of-shivering-in-cesarean-section-100632269","NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","FEMALE","40 Years",{"count":190,"type":21},90,[50],"This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[194,195,196,197,198,199],"Ondansetron","Lozenge","Intravenous","Prevention","Shivering","Cesarean Section",{"date":111,"type":30},{"date":202,"type":30},"2026-04-11",{"date":204,"type":21},"2026-08-30",{"name":36,"class":37},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":48,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":38},"100644175","subtransverse-process-interligamentary-plane-block-versus-rhomboid-intercostal-block-combined-with-sub-serratus-plane-block-for-analgesia-in-pediatric-thoracotomy-100644175","NCT07666334","Subtransverse Process Interligamentary Plane Block Versus Rhomboid Intercostal Block Combined With Sub-Serratus Plane Block for Analgesia in Pediatric Thoracotomy","Ultrasound- Guided Subtransverse Process Interligamentary Plane Block Versus Rhomboid Intercostal Block Combined With Sub-Serratus Plane Block for Analgesia in Pediatric Thoracotomy: A Randomized Controlled Study","Inclusion Criteria:\n\n* Pediatric patients between 6 to 12 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) Physical Status I - II.\n* Scheduled for thoracic surgery with thoracotomy incision under general anesthesia.\n\nExclusion Criteria:\n\n* Parents who refused regional anesthesia.\n* Patients were presented with advanced kidney, cardiac or liver diseases.\n* Coagulation and bleeding disorders.\n* Patients presented with skin or soft tissue infection at the proposed site of needle Insertion.\n* Patients with cognitive impairment.","6 Years","12 Years",{"count":216,"type":21},75,[50],"This study aims to compare ultrasound guided subtransverse process interligamentary plane block versus rhomboid intercostal block combined with sub-serratus plane block for postoperative analgesia in pediatric thoracotomy.",[220,221,222,150,223],"Subtransverse Process Interligamentary Plane Block","Rhomboid Intercostal Block","Sub-Serratus Plane Block","Pediatric Thoracotomy","2026-06-18",{"date":57,"type":30},{"date":227,"type":30},"2025-09-01",{"date":229,"type":21},"2027-09-01",{"name":36,"class":37},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":38},"100644267","fibrinogen-to-albumin-ratio-as-a-predictor-of-acute-respiratory-distress-syndrome-in-traumatic-brain-injury-100644267","NCT07664358","Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury","Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Patients With Traumatic Brain Injury: The Prospective, Observational, Multi-center FARDS Study","FARDS","Inclusion Criteria:\n\n* Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury\n* Admission to the ICU within 24 hours of injury.\n* Patients will be expected to remain under hospital care for follow-up\n* Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission.\n* Informed consent will be obtained from a legally authorized representative.\n\nExclusion Criteria:\n\n* Preexisting advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy.\n* Pre-existing ARDS on admission.\n* Recipient of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling.\n* Use of anticoagulant or fibrinolytic therapy before admission.\n* Active malignancy or severe systemic infection at admission.\n* Direct sever lung injury\n* Pregnancy\n* Refusal of consent",{"count":240,"type":21},350,"this study aims to assess the ability of fibrinogen-to-albumin ratio to predict the development of Acute respiratory distress syndrome in traumatic brain injury patients.",[243,244,245],"Fibrinogen Albumin Ratio","ARDS","TBI (Traumatic Brain Injury)","2026-06-17",{"date":57,"type":30},{"date":27,"type":21},{"date":250,"type":21},"2026-12-30",{"name":36,"class":37},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":48,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":270,"locationsCount":38},"100641068","percutaneous-neurostimulation-in-knee-osteoarthritis-100641068","NCT07637682","Percutaneous Neurostimulation in Knee Osteoarthritis","Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis","Inclusion Criteria:\n\n1. adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.\n2. Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).\n3. patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.\n\nExclusion Criteria:\n\n1. Patients with OA show improvement in pain after physiotherapy.\n2. patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.\n3. pregnant patients.\n4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.\n5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.\n6. people who had received an intra-articular knee injection within the last 6 months.\n7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.",{"count":20,"type":21},[50],"Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis",[263,264],"Osteoarthritis (OA) of the Knee","Neuromodulation","2026-06-16",{"date":224,"type":30},{"date":268,"type":30},"2026-06-02",{"date":134,"type":21},{"name":36,"class":37},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":187,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":48,"phases":281,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":38},"100641552","phase-3-intravenous-lidocaine-to-prevent-post-fundal-pressure-headache-during-cesarean-section-100641552","NCT07661758","Intravenous Lidocaine to Prevent Post-Fundal Pressure Headache During Cesarean Section","Pre-emptive Single Intravenous Lidocaine Dose to Prevent Post-Fundal Pressure Headache During Cesarean Section: The LID-HEAD Multi-center Randomized Controlled Trial","LID-HEAD","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* American Society of Anesthesiologists (ASA) Physical Status II\n* Scheduled for elective cesarean section under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients declined to participate in the trial,\n* Patients with history of any type of headache, mental illness, or cerebrovascular diseases\n* Previous epidural insertion for painless labor or any other indications;\n* Patients on opioid or analgesic medications;\n* Those with pregnancy-induced hypertension or diabetic patients,\n* Allergy to lidocaine;\n* Contraindication or failure of spinal anesthesia.",{"count":280,"type":21},680,[282],"PHASE3","This prospective randomized controlled multicenter study will be conducted to evaluate the effects of pre-emptive IV lidocaine dose on the incidence and severity of intraoperative headache that may occur after the extra-abdominal manual uterine fundal pressure in patients undergoing cesarean section under spinal anesthesia.",[285,286,287],"Intravenous Lidocaine","Fundal Pressure","Headache",{"date":152,"type":30},{"date":27,"type":21},{"date":291,"type":21},"2026-11-02",{"name":36,"class":37},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":48,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":38},"100632675","phase-3-nicorandil-as-anti-inflammatory-in-rheumatoid-arthritis-100632675","NCT07516769","Nicorandil as Anti-inflammatory in Rheumatoid Arthritis","Clinical Study Evaluating the Effect of Nicorandil as Anti-inflammatory and Immune Modulatory in Patients With Rheumatoid Arthritis","RA","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) i.e., 28 joints disease activity score (DAS-28) \\>2.6.\n* Patients receiving the conventional DMARDs\n\nExclusion Criteria:\n\n* Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.\n* Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.\n* Patients receiving oral prednisolone greater than 15mg\u002Fday.\n* Patients with hypersensitivity to study medications.\n* Patients using antioxidants.\n* Pregnant and lactating females.","70 Years",{"count":303,"type":21},46,[282],"This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.",[307],"Rhumatoid Arthisis",[307,309],"Nicorandil",{"date":224,"type":30},{"date":312,"type":30},"2024-11-01",{"date":314,"type":21},"2027-04",{"name":36,"class":37},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":187,"minAge":18,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":48,"phases":325,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":38},"100641608","subtransverse-interligamentary-block-versus-paravertebral-block-for-quality-of-recovery-after-mastectomy-100641608","NCT07647367","Subtransverse Interligamentary Block Versus Paravertebral Block for Quality of Recovery After Mastectomy","Ultrasound-Guided Subtransverse Interligamentary Plane Block Versus Thoracic Paravertebral Block for Quality of Recovery After Modified Radical Mastectomy: A Randomized Non-Inferiority Trial","Inclusion Criteria:\n\n* Adult female patients aged 18 to 65 years with American Society of Anesthesiologists (ASA) Physical Status I - III, who were scheduled for unilateral MRM surgery under general anesthesia and able to understand and complete the QoR-15 questionnaire\n\nExclusion Criteria:\n\n* • Patients declined to participate in the trial.\n\n  * History of allergy to the used local anesthetic (LA) drugs.\n  * Patients with cutaneous lesions at the needle entry point.\n  * Coagulopathy or current anticoagulant therapy contraindicating regional block.\n  * Patients with severe hepatic, renal, cardiac, or respiratory disease.\n  * Psychiatric or cognitive disorder interfering with QoR-15 assessment\n  * Chronic opioid use or chronic pain syndrome.\n  * Failed block.\n  * Morbid obesity (body mass index \\>40 kg\u002Fm2)\n  * Intraoperative major complications requiring postoperative ICU admission.\n  * Pregnancy","65 Years",{"count":125,"type":21},[50],"This prospective randomized controlled double blinded non-inferiority study will be carried out in Tanta University Hospitals for duration of 6 months from June 2026 to December 2026 on 60 female patients scheduled for unilatral modified radical mastectomy under general anesthesia.",[328,329],"Quality of Recovery (QoR-15)","Modified Radical Mastectomy",[331,332,333],"subtransverse interligamentary plane block","modified radical mastectomy","quality of recovery","2026-06-14",{"date":246,"type":30},{"date":337,"type":21},"2026-06",{"date":339,"type":21},"2027-01",{"name":36,"class":37},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":71,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":48,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":359,"leadSponsor":361,"locationsCount":38},"100641127","phase-3-subcutaneous-calcitonin-in-acute-herpes-zoster-100641127","NCT07655804","Subcutaneous Calcitonin in Acute Herpes Zoster","The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \\\u003C 7 days) and moderate to severe pain.\n\nExclusion Criteria:\n\n* Coagulation abnormalities\n* Pre-existing other pain syndrome or psychological disorders.\n* Severe hepatic, cardiovascular, or renal disorders.\n* Allergy to calcitonin.",{"count":349,"type":21},168,[282],"This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.",[353,354,355],"Calcitonin","Subcutaneous","Acute Herpes Zoster","2026-06-13",{"date":224,"type":30},{"date":27,"type":21},{"date":360,"type":21},"2027-10-01",{"name":36,"class":37},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":48,"phases":373,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":383,"leadSponsor":385,"locationsCount":38},"100641205","phase-2-oral-versus-intravenous-magnesium-on-emergence-delirium-100641205","NCT07655817","Oral Versus Intravenous Magnesium on Emergence Delirium","Effect of Oral Versus Intravenous Magnesium on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Two-Center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Children aged 4 to 7 years\n* American Society of Anesthesiologist (ASA) Status I or II\n* Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia.\n\nExclusion Criteria:\n\n* Parents declined to participate in the trial\n* Behavioral changes, neurological or psychiatric problems\n* Anticonvulsant or sedative drugs\n* Physical or developmental abnormalities\n* Allergies to magnesium\n* cardiovascular, renal, bone, or gastrointestinal diseases.","4 Years","7 Years",{"count":372,"type":21},360,[374,282],"PHASE2","This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.",[377,378,379,380],"Magnesium","Emergence Delirium","Children","Adenotonsillectomy",{"date":224,"type":30},{"date":57,"type":21},{"date":384,"type":21},"2026-12-25",{"name":36,"class":37},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":48,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100643098","icg-in-colon-cancer-100643098","NCT07638956","ICG in Colon Cancer","A Prospective Study of Indocyanine Green (ICG) Fluorescence-Guided Lymphatic Mapping During Laparoscopic Colon Cancer Resection","ICG","Inclusion Criteria:\n\nAge \\>= 18 years.\n\n\\- Histologically confirmed colon adenocarcinoma.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction\u002Fperforation with sepsis) requiring urgent operation.\n* Known allergy or contraindication to ICG (including prior anaphylaxis to ICG; severe hypersensitivity history per anesthesia assessment).\n* Pregnancy or breastfeeding.\n* Severe hepatic failure (because ICG clearance is hepatobiliary) or other contraindication determined by anesthesia team.\n* Planned palliative resection only.\n* ASA physical status IV or patients otherwise deemed unfit for elective curative colectomy.",{"count":7,"type":21},[50],"The aim of this study is to evaluate the role of indocyanine green (ICG) injection in fluorescence-guided lymphatic mapping during laparoscopic colon cancer resection. This is a single-center prospective single-arm pilot clinical study that will include at least 25 patients with resectable colon cancer. All enrolled patients will undergo intraoperative subserosal ICG-guided lymphatic mapping before dissection, and intravenous ICG perfusion assessment before anastomosis. The primary goal is to determine the proportion of analyzable pN+ patients in whom all metastatic lymph nodes identified on final histopathology are located within the ICG-mapped lymphatic basin.",[398,399],"Colon Cancer","ICG (Indocyanine Green)",{"date":401,"type":30},"2026-06-12",{"date":403,"type":21},"2026-06-01",{"date":405,"type":21},"2028-11-01",{"name":36,"class":37},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":414,"targetDuration":4,"studyType":48,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":4},"100643005","phase-2-vitamin-d-in-diabetic-neuropathy-100643005","NCT07644520","Vitamin D in Diabetic Neuropathy","Effect of Vitamin D Supplementation on Neuropathic Pain, Sleep Quality, and Quality of Life in Patients With Diabetic Peripheral Neuropathy","Inclusion criteria\n\nParticipants must fulfill all the following:\n\n1\\. Age between 18 and 75 years 2. Diagnosed with type 2 diabetes mellitus according to ADA criteria 3. Clinically diagnosed diabetic peripheral neuropathy 4. Neuropathic symptoms for at least 3 months 5. Vitamin D insufficiency or deficiency:\n\n* Serum 25(OH)D \\\u003C 30 ng\u002FmL 6. Stable antidiabetic treatment for at least 3 months Exclusion criteria\n\n  1. Type 1 diabetes mellitus\n  2. Current vitamin D supplementation within the previous 3 months\n  3. Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n  4. Severe hepatic impairment\n  5. Hypercalcemia\n  6. Malabsorption syndromes\n  7. Pregnancy or lactation\n  8. Peripheral neuropathy due to causes other than diabetes:\n* Vitamin B12 deficiency\n* Hypothyroidism\n* Alcoholic neuropathy\n* Chemotherapy-induced neuropathy 9. Active malignancy 10. Severe psychiatric illness",{"count":415,"type":21},150,[374,282],"Introduction Diabetic peripheral neuropathy (DPN) is among the most common chronic complications of diabetes mellitus and represents a major cause of morbidity, impaired quality of life, sleep disturbance, chronic pain, and functional disability.(Kurz et al., 2026) The pathogenesis of DPN is multifactorial and involves oxidative stress, chronic inflammation, endothelial dysfunction, mitochondrial injury, and microvascular ischemia, leading to progressive nerve damage.(Yang et al., 2025) Despite the availability of symptomatic therapies such as gabapentin, pregabalin, and duloxetine, many patients continue to experience persistent neuropathic symptoms, poor sleep quality, and impaired daily functioning. Existing pharmacological therapies are often associated with incomplete response, adverse effects, and high economic burden.(Kaye et al., 2025) Recently, vitamin D has attracted attention beyond its classical role in calcium and bone metabolism. Experimental and clinical evidence suggest that vitamin D possesses neuroprotective, anti-inflammatory, immunomodulatory, and antioxidative properties. Vitamin D receptors are widely distributed in neuronal tissues, Schwann cells, and immune cells, suggesting a potential role in nerve repair and modulation of neuropathic pain pathways.(Liu et al., 2025) Several observational studies have demonstrated a high prevalence of vitamin D deficiency among patients with diabetic neuropathy, and low serum vitamin D levels have been associated with increased neuropathic pain severity and poorer quality of life. However, available interventional studies remain limited and have produced inconsistent findings regarding the therapeutic benefit of vitamin D supplementation in DPN.(Ou et al., 2021) Therefore, this study aims to evaluate whether vitamin D supplementation can improve neuropathic pain, sleep quality, and health-related quality of life among patients with diabetic peripheral neuropathy.",[419],"Diabetic Nephropathy Type 2","2026-06-08",{"date":401,"type":30},{"date":423,"type":21},"2026-10-01",{"date":425,"type":21},"2027-10-30",{"name":36,"class":37},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":48,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":444,"leadSponsor":445,"locationsCount":38},"100643050","routine-rehabilitation-versus-shock-wave-therapy-for-scapular-dyskinesis-100643050","NCT07633340","Routine Rehabilitation Versus Shock Wave Therapy for Scapular Dyskinesis","Routine Rehabilitation Versus Shock Wave Therapy for Patients With Scapular Dyskinesis","Inclusion Criteria:\n\n* This study included 100 patients with scapular dyskinesis. The patients were divided into 2 groups: one group was treated with ESWT and routine rehabilitation, and the second group was treated with routine rehabilitation only. Adult patients with scapular dyskinesia who exhibited signs of dyskinesia for at least 6 months before enrolment in the study will be selected.\n\nExclusion Criteria:\n\n1. History of shoulder or thorax trauma or surgery.\n2. The back pain involved the cervical spine and thoracic spine.\n3. Participants with neurologic deficits\n4. history of inflammatory conditions such as ankylosing spondylitis\n\n4- Certain situations where shockwave therapy is not recommended. These include:\n\nAbsolute contraindications:\n\n* Active infection (i.e., osteomyelitis)\n* Malignant tumors, particularly at the treatment site (focused shockwave)\n* Pregnancy\n\nRelative Contraindications:\n\n* The brain or nerve in the treatment focus\n* Treatment focused on the lungs or pleura\n* Significant coagulopathy (increased risk of bleeding, such as haemophilia)\n* Epiphyseal plate in treatment focus\n\nImportant considerations:\n\n* Cardiac pacemakers or other implantable devices\n* Current nonsteroidal anti-inflammatory drug use\n* Current anticoagulation use\n* Recent corticosteroid injections (receiving a steroid injection into the area to be treated within the previous 12 weeks).",{"count":20,"type":21},[50],"It has been proposed that altered scapular muscle function can contribute to alterations in shoulder kinematics, which often lead to SD and are frequently associated with other shoulder pathologies, such as RC tears, labrum tears, impingement syndrome, and glenohumeral joint instability. However, whether SD leads to the development of these diseases or is a consequence has yet to be clarified. Changes in scapular kinematics can be attributed not only to altered scapular recruitment patterns (e.g., altered serratus anterior muscle activity) or muscle performance (e.g., force imbalance in the upper and lower trapezius muscles) but also to flexibility deficits in the soft tissue surrounding the scapula, which may restrict normal scapular movement during daily activities and sport- specific movements. Although many studies have investigated the optimal management method, to date, there is no consensus. Conservative approaches involve not only physiotherapy but also other techniques, such as extracorporeal shockwave therapy.",[25,438],"Shockwave Therapy",[440],"Scapular dyskinesis","2026-06-06",{"date":132,"type":30},{"date":403,"type":30},{"date":34,"type":21},{"name":36,"class":37},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":469},"100623830","dysphagia-in-rheumatoid-arthritis-100623830","NCT07401732","Dysphagia in Rheumatoid Arthritis","Prediction of Dysphagia Severity and Diagnosis of Its Possible Causes in Rheumatoid Arthritis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients with Rheumatoid arthritis defined by the American College of Rheumatology\u002FEuropean League Against Rheumatism collaborative initiative (ACR\u002FEULAR) 2010 classification criteria.\n* Patients aged above 18 years old, well-orientated, and cooperative.\n\nExclusion Criteria:\n\n* concomitant cancer diagnosis, pregnancy.\n* jaw-related traumas, teeth and gum diseases.\n* other rheumatologic conditions\n* other comorbidities.\n* other causes of TMJ arthritis, patients with TMJ, palatal or tongue congenital abnormalities, and patients who underwent TMJ injections in the last six months.\n* Patients with any language disorders or intellectually handicapped (as certain questions depend on the patient's ability to comprehend and express their emotions regarding their issue) and patients with anatomical anomalies impeding the functionality of flexible nasofibroscopy.\n* Any apparent causes of dysphagia other than RA.",{"count":454,"type":21},137,"The primary goal of this cross-sectional study is to assess risk factors\u002Fpredictors for dysphagia severity in RA.\n\nThe secondary goals include demonstrating whether flexible fiberoptic pharyngolaryngoscopy can diagnose joint-affection-induced dysphagia in patients with rheumatoid arthritis (RA) and whether both oropharyngeal and esophageal dysphagia are present among these patients.\n\nThe main questions it aims to answer are\n\n* What are the predictors that are associated with dysphagia severity via flexible fiberoptic pharyngolaryngoscopy in rheumatoid arthritis patients?\n* Whether flexible fiberoptic pharyngolaryngoscopy can diagnose joint-affection-induced dysphagia in patients with RA?\n* Whether both oropharyngeal and esophageal dysphagia are present in patients with RA?",[457],"Rheumatoid Arthritis (RA",[459,460,461,462],"Flexible Endoscopic Evaluations of Swallowing","Temporomandibular joint","Deglutition disorders","cricoarytenoid",{"date":464,"type":30},"2026-06-09",{"date":466,"type":30},"2026-02-07",{"date":34,"type":21},{"name":36,"class":37},2,{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":476,"sex":94,"minAge":4,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":48,"phases":478,"briefSummary":479,"conditions":480,"keywords":484,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":38},"100640806","a-prospective-comparative-study-evaluating-the-safety-and-efficacy-of-transurethral-thulium-fiber-laser-holmium-laser-and-bipolar-enucleation-of-large-sized-prostate-100640806","NCT07627178","A Prospective Comparative Study Evaluating the Safety and Efficacy of Transurethral Thulium Fiber Laser, Holmium Laser and Bipolar Enucleation of Large Sized Prostate","Inclusion Criteria:\n\n* Male patients diagnosed with BPH\n* Clinical diagnosis of BPH with lower urinary tract symptoms.\n* IPSS ≥ 20 (severe symptoms)\n* Maximum urinary flow rate (Qmax) ≤ 10 mL\u002Fs\n* Prostate volume \\>100 mL (measured by transrectal ultrasound)\n* Failed medical therapy and fit for operation\n\nExclusion Criteria:\n\n* Prostate cancer (current or history).\n* Previous prostate surgery\n* Previous urethral surgery.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection.\n* Severe cardiovascular disease (ASA Class IV).\n* Previous pelvic radiation.\n* Urethral stricture\n* Urinary bladder stones.",true,{"count":190,"type":21},[50],"This study compares the safety and efficacy of three endoscopic enucleation techniques for large prostates (\\>100 mL) in patients with benign prostatic hyperplasia (BPH): Thulium Fiber Laser Enucleation (ThuFLEP), Holmium Laser Enucleation (HoLEP), and Bipolar Enucleation (B-TUEP). Ninety male patients with severe lower urinary tract symptoms (IPSS ≥20, Qmax ≤10 mL\u002Fs) who failed medical therapy will be randomized 1:1:1 into three groups of 30. Primary outcomes include IPSS, quality of life score, maximum flow rate (Qmax), and post-void residual at 1, 3, and 6 months postoperatively. Secondary outcomes include operative time, enucleation efficiency, blood loss, catheterization duration, hospital stay, and complication rates assessed by the Clavien-Dindo classification.",[481,482,483],"Benign Prostatic Hyperplasia (BPH)","Lower Urinary Tract Symptom","Bladder Outlet Obstruction",[485,486,487,488,489,490,491,492],"Prostate Enucleation","ThuLEP","HOLEP","Bi-TUEP","TFL","BPH Surgery","IPSS","Uroflowmetry","2026-06-03",{"date":495,"type":30},"2026-06-05",{"date":497,"type":30},"2025-10-21",{"date":499,"type":21},"2027-05-30",{"name":36,"class":37},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":508,"targetDuration":4,"studyType":48,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":523,"locationsCount":38},"100637353","us-vs-fl-guided-lumbar-nerve-root-injections-100637353","NCT07627308","US vs FL-Guided Lumbar Nerve Root Injections","Ultrasound-Guided Versus Fluoroscopy-Guided Selective Lumbar Nerve Root Injections for Lumbosacral Radiculopathy: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Clinical diagnosis of lumbar radiculopathy characterized by radicular pain, paresthesia, or weakness in a dermatomal distribution.\n* Magnetic Resonance Imaging (MRI)-confirmed nerve root compression due to disc herniation or foraminal stenosis.\n* Failure to respond to at least 3 months of conservative medical treatment.\n* Radiculopathy affecting the L4, L5, or combined L5-S1 levels (where the primary symptomatic level can be reliably targeted)\n\nExclusion Criteria:\n\n* Isolated S1 radiculopathy.\n* Significant spinal deformities, including scoliosis \\>20° or spondylolisthesis \\>Grade II.\n* History of prior lumbar spine surgery.\n* Bleeding disorders (International Normalized Ratio \\[INR\\] \\>2.5).\n* Severe uncontrolled diabetes mellitus (HbA1c \\>8%).\n* Advanced cardiac, renal, or hepatic disease.\n* Active systemic infection or localized infection at the injection site.\n* Known allergies to corticosteroids or local anesthetics.\n* Presence of progressive neurological deficits or cauda equina syndrome.\n* Peripheral neuropathies mimicking radiculopathy.\n* Pregnancy or breastfeeding.\n* Severe psychiatric illness or cognitive impairment affecting study compliance.",{"count":509,"type":21},64,[50],"The goal of this clinical trial is to learn if ultrasound-guided nerve root injections work as well as fluoroscopy (X-ray)-guided injections to treat lower back and leg pain caused by irritated nerves (lumbosacral radiculopathy) in adults aged 18 to 75 years old.\n\nThe main questions it aims to answer are:\n\n* Does ultrasound guidance lower pain as effectively as fluoroscopy guidance after 3 months?\n* Does one method help participants recover their ability to do daily activities better than the other?\n* Are ultrasound-guided injections as fast and safe for participants as fluoroscopy-guided injections? Researchers will compare ultrasound-guided nerve root injections to fluoroscopy-guided nerve root injections to see if ultrasound works to treat the pain just as well while allowing participants to avoid radiation exposure.\n\nParticipants will:\n\n* Receive one targeted nerve injection of medication (a steroid and numbing medicine) in their lower back using either ultrasound or fluoroscopy to guide the needle.\n* Stay at the clinic for 30 to 60 minutes after the procedure so researchers can check their safety.\n* Attend checkups at 1 week, 1 month, and 3 months to answer survey questions about their pain levels and daily functioning.",[513],"Lumbosacral Radiculopathy",[513,515,516,517],"Radicular Pain","Ultrasound-Guided","Fluoroscopy-Guided","2026-05-31",{"date":520,"type":30},"2026-06-04",{"date":403,"type":30},{"date":157,"type":21},{"name":36,"class":37},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":94,"minAge":18,"maxAge":71,"enrollmentInfo":532,"targetDuration":4,"studyType":48,"phases":533,"briefSummary":534,"conditions":535,"keywords":539,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":38},"100638532","pelvic-floor-therapies-for-lifelong-premature-ejaculation-100638532","NCT07627438","Pelvic Floor Therapies for Lifelong Premature Ejaculation","Electromagnetic Pelvic Floor Stimulation Versus Biofeedback-Assisted and Conventional Pelvic Floor Muscle Training in Men With Lifelong Premature Ejaculation: A Randomized Controlled Trial","PE-PFMT","Inclusion Criteria:\n\n* Men aged 18 to 50 years.\n* Diagnosis of lifelong premature ejaculation.\n* Intravaginal ejaculatory latency time less than 1 minute.\n* Ability and willingness to comply with the treatment protocol and follow-up visits.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Erectile dysfunction.\n* Neurological disease.\n* Previous pelvic surgery.",{"count":415,"type":21},[50],"This randomized controlled trial will compare three pelvic floor-based treatment modalities in men with lifelong premature ejaculation: electromagnetic pelvic floor stimulation, biofeedback-assisted pelvic floor muscle training, and conventional pelvic floor muscle training. A total of 150 men aged 18 to 50 years with lifelong premature ejaculation and stopwatch-measured intravaginal ejaculatory latency time of less than 1 minute will be randomly assigned to one of the three treatment groups. The primary outcome will be the change in intravaginal ejaculatory latency time from baseline to the end of treatment at 6 weeks. Secondary outcomes will include changes in Premature Ejaculation Diagnostic Tool score, International Index of Erectile Function-5 score, patient-reported ejaculatory control, sexual satisfaction, partner satisfaction, treatment adherence, and adverse events.",[536,537,538],"Premature Ejaculation","Lifelong Premature Ejaculation","Male Sexual Dysfunction",[540,541,542],"Pelvic floor muscle training","Biofeedback","Electromagnetic pelvic floor stimulation","2026-05-30",{"date":520,"type":30},{"date":546,"type":30},"2026-04-26",{"date":314,"type":21},{"name":36,"class":37},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":187,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":48,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":567,"leadSponsor":568,"locationsCount":38},"100640200","combination-of-superior-hypogastric-plexus-block-and-transversus-abdominis-plane-block-in-abdominal-hysterectomies-100640200","NCT07606781","Combination of Superior Hypogastric Plexus Block and Transversus Abdominis Plane Block in Abdominal Hysterectomies","Analgesic Effect of Combination of Superior Hypogastric Plexus Block and Transversus Abdominis Plane Block in Abdominal Hysterectomies: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Undergoing abdominal hysterectomies under general anesthesia (GA).\n\nExclusion Criteria:\n\n* History of allergies to local anesthetics.\n* Body mass index (BMI) \\>35 kg\u002Fm2.\n* Opioid dependency.\n* Cognitive impairment.\n* Bleeding or coagulation disorders.\n* Psychiatric and neurological disorder.\n* Local infection at the site of injection.\n* Severe heart, lung, liver, and renal dysfunction.",{"count":557,"type":21},44,[50],"This study aims to evaluate the analgesic effect of superior hypogastric plexus block combined with transversus abdominis plane block in abdominal hysterectomies.",[561,562,563],"Superior Hypogastric Plexus Block","Transversus Abdominis Plane Block","Abdominal Hysterectomies",{"date":565,"type":30},"2026-05-27",{"date":155,"type":30},{"date":423,"type":21},{"name":36,"class":37},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":476,"sex":17,"minAge":575,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":48,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":4},"100637827","measuring-the-changes-of-the-intraocular-pressure-after-corneal-cross-linking-using-corvis-ct-100637827","NCT07599020","Measuring the Changes of the Intraocular Pressure After Corneal Cross Linking Using Corvis CT","Inclusion Criteria:\n\n* Patients who will corneal cross linking for mild degree of keratoconus, age between 19 and 35 years old\n\nExclusion Criteria:\n\n* Corneal scarring.\n* Previous corneal infections.\n* Minimum corneal thickness at the thinnest location less than 400 µm.\n* History of uveitis or ocular allergy.\n* Pre-existing glaucoma.","19 Years","35 Years",{"count":38,"type":21},[50],"To evaluate the changes that occur in the intraocular pressure before and after corneal cross linking using Corvis CT.",[581,582],"Keratoconus","Intraocular Pressure",{"date":584,"type":30},"2026-05-20",{"date":586,"type":21},"2026-07-10",{"date":588,"type":21},"2027-02-10",{"name":36,"class":37},""]